149 related articles for article (PubMed ID: 36708563)
1. ADAM10 Gene Polymorphism and Its Relationship to Hepatocellular Carcinoma in Egyptian HCV Patients Receiving Direct-Acting Antiviral Therapies (DAAs).
Ghanem S; El Gedawy G; Yehia S; Bedair H; Awad S; Abdel-Razek W; Elhelbawy M; El-Sabaawy D; Elfert AY
Asian Pac J Cancer Prev; 2023 Jan; 24(1):149-155. PubMed ID: 36708563
[TBL] [Abstract][Full Text] [Related]
2. Prospective Comparison of Hepatocellular Carcinoma Behavior and Survival of Patients who Did or Did not Receive HCV Direct-Acting Antivirals.
El-Kassas M; Sayed H; Omran D; Eldahrouty AH; Elbaz T; Kamal E
Asian Pac J Cancer Prev; 2023 Feb; 24(2):597-605. PubMed ID: 36853310
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
4. De novo hepatocellular carcinoma in cirrhotic hepatitis C virus: Are directly acting antivirals beneficial?
Montasser IF; Ibrahim AA; Farid HM; Al Balakosy AM
Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101517. PubMed ID: 32900667
[TBL] [Abstract][Full Text] [Related]
5. Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.
Ghanm SE; Shebl NA; El Sayed IET; Abdel-Bary HM; Saad BF; Othman Saad W
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3203-3210. PubMed ID: 34710996
[TBL] [Abstract][Full Text] [Related]
6. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Cordie AA; Hassan EM; Omran DA; Leithy R; Elbaz TM
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):39-43. PubMed ID: 29064851
[TBL] [Abstract][Full Text] [Related]
7. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
8. lnc-HOTAIR predicts hepatocellular carcinoma in chronic hepatitis C genotype 4 following direct-acting antivirals therapy.
El-Khazragy N; Elshimy AA; Hassan SS; Shaaban MH; Bayoumi AH; El Magdoub HM; Ghozy S; Gaballah A; Aboelhussein MM; Abou Gabal HH; Bannunah AM; Mansy AE
Mol Carcinog; 2020 Dec; 59(12):1382-1391. PubMed ID: 33074585
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma Occurrence/Recurrence after Direct-Acting Antivirals for Hepatitis C in Egyptian Cohort: Single-Center Experience.
Lashen SA; Shamseya MM; Madkour MA
Dig Dis; 2019; 37(6):488-497. PubMed ID: 31216532
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
[TBL] [Abstract][Full Text] [Related]
11. Impact of interleukin IL-6 rs-1474347 and IL-10 rs-1800896 genetic polymorphisms on the susceptibility of HCV-infected Egyptian patients to hepatocellular carcinoma.
Abd El-Baky RM; Hetta HF; Koneru G; Ammar M; Shafik EA; Mohareb DA; Abbas El-Masry M; Ramadan HK; Abu Rahma MZ; Fawzy MA; Fathy M
Immunol Res; 2020 Jun; 68(3):118-125. PubMed ID: 32504406
[TBL] [Abstract][Full Text] [Related]
12. Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study.
Ramadan HK; Badr G; Ramadan NK; Sayed A
Pathog Dis; 2021 Mar; 79(3):. PubMed ID: 33524139
[TBL] [Abstract][Full Text] [Related]
13. P53 is a risk factor of de-novo hepatitis C-related hepatocellular carcinoma treated with direct-acting antivirals: a case-control study.
Omran M; Fouda M; Abdelwahab AO; Nabeel MM; Abdelaziz AO; Omran D; Shousha HI
Eur J Gastroenterol Hepatol; 2022 Feb; 34(2):220-226. PubMed ID: 33079785
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
[TBL] [Abstract][Full Text] [Related]
15. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M
Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 28 Polymorphisms and Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy for Chronic Hepatitis C.
Simili A; Mazzella G; Ravaioli F; Festi D; Bacchi-Reggiani ML; Porro A; Bazzoli F; Azzaroli F
J Gastrointestin Liver Dis; 2019 Dec; 28(4):449-456. PubMed ID: 31826071
[TBL] [Abstract][Full Text] [Related]
17. IL28B rs12979860 gene polymorphism in Egyptian patients with chronic liver disease infected with HCV.
Zekri AR; Salama H; Medhat E; Bahnassy AA; Morsy HM; Lotfy MM; Ahmed R; Darwish T; Marei MS
Asian Pac J Cancer Prev; 2014; 15(17):7213-8. PubMed ID: 25227816
[TBL] [Abstract][Full Text] [Related]
18. Study of Toll-like Receptor 3 Gene Polymorphism as a Novel Risk Factor for HCV-related Hepatocellular Carcinoma in Egypt.
El-Sharawy S; Negm OE; Abd-Elsalam S; El-Sorogy HA; Shehata MAH
Curr Cancer Drug Targets; 2020; 20(5):382-389. PubMed ID: 32189594
[TBL] [Abstract][Full Text] [Related]
19. IL12 Gene Polymorphism in Association with Hepatocellular Carcinoma in HCV-infected Egyptian Patients.
Elsayed HM; Nabiel Y; Sheta T
Immunol Invest; 2017 Feb; 46(2):123-133. PubMed ID: 27819525
[TBL] [Abstract][Full Text] [Related]
20. IL-28B rs12979860 polymorphism affect the course of chronic hepatitis and the development of HCC in Egyptian patients with hepatitis C type 4.
Attallah AM; Omran D; Marie MS; Abdelrazek M; Salama A; El Essawey R; Mobarak L; Maklad S; Omar A
Br J Biomed Sci; 2018 Oct; 75(4):157-162. PubMed ID: 29914308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
